Physician profile
Brandon Wei
NPI 1902556962
$3,836.26
in general payments reported to CMS, 2019-2025
27 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.92 · 2023: $709 · 2024: $1,847 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $419.75 | 2024-2025 | |
| Ucb, INC. | $362.21 | 2023-2024 | Rystiggo, Briviact, Fintepla |
| Sk Life Science, INC. | $322.94 | 2025 | |
| Abbvie INC. | $279.97 | 2023-2025 | Botox |
| Csl Behring | $253.68 | 2023-2025 | Hizentra |
| Genentech USA, INC. | $252.06 | 2022-2025 | Evrysdi, Ocrevus Zunovo, Enspryng |
| Acadia Pharmaceuticals INC | $252.06 | 2024-2025 | Nuplazid, Daybue |
| Argenx US, INC. | $243.02 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $208.63 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $172.35 | 2023-2024 | Andexxa, Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $141.62 | 2024-2025 | Hyqvia |
| Genzyme Corporation | $126.25 | 2023-2024 | |
| Biogen, INC. | $113.55 | 2023-2025 | Vumerity, Tysabri, Spinraza |
| Alexion Pharmaceuticals, INC. | $101.07 | 2023-2024 | Ultomiris, Soliris |
| Springworks Therapeutics, INC. | $74.32 | 2025 | Gomekli |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.28 | 2024 | Uplizna |
| Grifols USA, LLC | $71.91 | 2023-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $60.66 | 2024 | Xarelto |
| Janssen Biotech, INC. | $59.55 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $50.65 | 2023 | Nuedexta |
| Horizon Therapeutics Plc | $44.66 | 2022 | |
| Tanabe Pharma America, INC. | $42.78 | 2023 | |
| Emd Serono, INC. | $36.57 | 2023 | Mavenclad |
| Neurelis, INC. | $23.27 | 2023 | Valtoco |
| Amicus Therapeutics, INC. | $19.96 | 2025 | |
| Pfizer INC. | $16.65 | 2023 | |
| Microtransponder, INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.